Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibilitySandoz would acquire Just-Evotec Biologics (JEB) activities in Toulouse, France, including proprietary pl ...

ImmunoPrecise Antibodies (IPA) Q4 2025 Earnings Call July 29, 2025 10:30 AM ET Speaker0Good morning, ladies and gentlemen, and thank you for joining us today for ImmunoPrecise Antibody's Fourth Quarter and Fiscal Year End twenty twenty five Earnings Call. We appreciate your time and interest in IPA. Today's call will be led by our CEO, Doctor. Jennifer Bass and Interim CFO, Joe Scheffler. They will provide a review of our financial performance, strategic initiatives and key operational highlights for the fo ...

WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects a version issued on July 25, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety. iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical re ...

WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects the version issued on July 24, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety. iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical ...

Core Viewpoint - iSpecimen Inc. has successfully closed a public offering of 5,714,283 shares at a price of $0.70 per share, raising approximately $4 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering was conducted on a firm commitment basis, with WestPark Capital, Inc. serving as the Sole Book-Runner [2]. - The offering price was set at $0.70 per share, resulting in gross proceeds of around $4 million [1][2]. Group 2: Use of Proceeds - The company plans to allocate $1,500,000 for marketing and advertising services from IR Agency LLC [2]. - An initial milestone payment of $1,000,000 will be made under a definitive agreement with Sales Stack Solutions Corp. [2]. - The remaining funds will be used for working capital and general corporate purposes [2]. Group 3: Company Overview - iSpecimen operates an online marketplace connecting scientists with healthcare providers for biospecimens needed in medical research [5]. - The company utilizes proprietary, cloud-based technology to facilitate searches for specimens and patients across a network of healthcare organizations [5].

WOBURN, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of an underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross p ...

Core Insights - Amneal Pharmaceuticals reported preliminary financial results for Q2 2025, indicating robust growth and expectations to meet or exceed full-year guidance [1][3] - The company received FDA approval for Brekiya® autoinjector for migraine treatment and noted strong uptake of CREXONT® [3] - Amneal anticipates a BLA submission for a proposed biosimilar to XOLAIR® in Q4 2025, highlighting a strong pipeline for future growth [3] Financial Performance - Net revenue is projected to be between $720 million and $730 million, reflecting an approximate 3% increase compared to Q2 2024 [7] - Income before income taxes is expected to range from $45 million to $56 million, a significant increase from $20 million in the same period of 2024 [7] - Adjusted EBITDA is projected to be between $180 million and $185 million, marking an approximate 13% increase from Q2 2024 [7] Leverage Metrics - Gross leverage decreased to 3.8x as of June 30, 2025, down from 4.1x as of December 31, 2024 [7] - Net leverage also decreased to 3.7x as of June 30, 2025, compared to 3.9x at the end of 2024, attributed to higher profitability and continued debt reduction [7]

Core Viewpoint - iRhythm Technologies, Inc. will release its financial results for Q2 2025 on July 31, 2025, followed by a conference call to discuss the results [1] Company Overview - iRhythm Technologies is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease [3] - The company utilizes wearable biosensors and cloud-based data analytics combined with proprietary algorithms to transform data from millions of heartbeats into clinically actionable information [3] - iRhythm aims to enhance patient care by providing better data, insights, and health outcomes [3] Conference Call Details - The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET on the same day as the financial results release [1] - Interested parties can access a live and archived webcast of the conference call on the company's investor website [2]

Core Insights - Fifty1 AI Labs, LLC has announced a strategic partnership with the intent to acquire BioSpark AI Technologies Inc., aiming to revolutionize drug repurposing through advanced AI technologies [1][4] - The collaboration will integrate BioSpark's AI and large language model (LLM) platform with Fifty1 AI Labs' predictive modeling to enhance the analysis of extensive medical literature [2][3] Group 1: Partnership and Acquisition - The partnership is designed to leverage AI to extract transformative insights from medical literature, thereby advancing functional medicine and preventative care [1][4] - Fifty1 AI Labs intends to fully acquire BioSpark, which will enhance its capabilities in identifying promising drug repurposing candidates [3][4] Group 2: Technological Integration - BioSpark's proprietary AI platform automates the extraction and structuring of clinical data, which will significantly improve the efficiency of identifying therapeutic patterns [2][3] - The integration of BioSpark's capabilities with Fifty1 AI Labs' Bayesian inference and polypharmacy modeling will create a new approach to drug repurposing based on real-world clinical data [3][4] Group 3: Strategic Vision - The alliance aims to dominate preventative healthcare through personalized, data-driven strategies and rapid identification of drug candidates [4][5] - Both companies share a commitment to enhancing human expertise with ethical AI tools, focusing on opportunities in functional medicine that traditional trials may overlook [5][6] Group 4: Company Background - BioSpark AI Technologies Inc. specializes in organizing real-world clinical data using proprietary AI and LLM technologies and holds a U.S. patent for its automation system [6] - Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., focuses on AI-driven functional medicine, addressing critical needs in performance health and chronic disease prevention [7][8]

Financial Performance - Operating revenues increased to NOK 2,045 million in Q2 2025, up from NOK 1,949 million in the same period last year [1] - EBITDA reached NOK 522 million, compared to NOK 510 million in the previous year [1] - Profit before tax was NOK 326 million, slightly up from NOK 322 million [2] - Earnings per share increased to NOK 2.56 from NOK 2.45 [2] Segment Performance - BioSolutions saw improved results driven by continued growth in sales to agriculture [2][3] - BioMaterials experienced an increase in results due to higher sales prices, improved product mix, and increased sales volume, although this was partly offset by higher wood costs [2] - Fine Chemicals reported a weaker result primarily due to lower sales prices for bioethanol [2] Market Conditions - Positive net currency effects were noted across all areas [2] - The company’s President and CEO highlighted strong sales to agriculture and price increases for specialty cellulose as key drivers for improved results in BioSolutions and BioMaterials [3]